Core Viewpoint - The Shanghai Stock Exchange is set to review the IPO application of BaiAo SaiTu (Beijing) Pharmaceutical Technology Co., Ltd. on September 24, 2025, following its acceptance on June 20, 2023 [1] Company Overview - BaiAo SaiTu was established in 2009 and operates as a preclinical CRO and biotechnology company [1] - The company offers various innovative animal models and preclinical pharmaceutical research services based on its self-developed gene editing technology [1] Technology and Services - BaiAo SaiTu utilizes its proprietary RenMice fully human antibody mouse platform, which includes multiple series such as RenMab, RenLite, RenNano, RenTCR, and RenTCR-mimic [1] - The platform targets nearly a thousand potential drug targets in the human body for large-scale drug discovery and development [1] - The company also engages in the transfer, licensing, or collaborative development of promising antibody molecules [1]
百奥赛图科创板IPO将于9月24日上会